Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Xing Guo,Donghua He,Jing Chen,Xuanru Lin,Qingxiao Chen,Haimeng Yan,Xi Huang,Yi Li,Li Yang,Enfan Zhang,Yang,Wenjun Wu,Jingsong He,He Huang,Zhen Cai
DOI: https://doi.org/10.1182/blood.v128.22.2086.2086
IF: 20.3
2016-01-01
Blood
Abstract:Background: Multiple myeloma (MM) is the second mostly diagnosed disease among hematological malignancies after lymphoma. With the novel agents, the survival of MM patients has been improved significantly but still remains incurable because of drug resistance. Studies have found that high-mobility group box 1 protein (HMGB1) was involved in inflammation, angiogenesis, and cancer invasion progression, metastasis, and drug resistance. Our research was aimed at exploring the role of HMGB1 in MM cell proliferation and drug resistance.
What problem does this paper attempt to address?